SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia? SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia?

Observational study finds an increased amputation risk with diuretic use in people with diabetes, suggesting that the hypovolemic mechanism may also explain the amputation risk seen with canagliflozin.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news